Related Experiment Video
Updated: Aug 16, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
Diabetes Patients' Acceptance of Injectable Treatment, a Scientometric Analysis
Ileana Pantea1, Nadinne Roman1, Angela Repanovici2
1Faculty of Medicine, Transilvania University of Brasov, 500036 Brasov, Romania.
Life (Basel, Switzerland)
|December 23, 2022
Summary
Understanding patient adherence to injectable diabetes treatments is crucial for managing this global health issue. Key factors include glycemic control, lifestyle, healthcare services, medication, digitalization, and policies, all impacting treatment success.
Area of Science:
- Endocrinology
- Public Health
- Health Services Research
Background:
- Diabetes mellitus presents significant global health challenges with high economic costs.
- Beyond pancreatic dysfunction, numerous systemic factors contribute to diabetes prevalence.
- Patient adherence to injectable diabetes treatments is a critical, yet often overlooked, aspect of disease management.
Purpose of the Study:
- To identify key factors influencing patient adherence to injectable diabetes treatments.
- To map the research landscape concerning adherence challenges in diabetes care.
- To provide a foundation for future research aimed at improving treatment adherence.
Main Methods:
- A scientometric analysis was conducted using the Web of Science database.
- A comprehensive literature search was performed to identify relevant studies.
- Data were analyzed to generate a scientometric map and identify research clusters.
Main Results:
- Six major directions influencing adherence were identified: glycemic control, lifestyle adjustments, healthcare services, medication therapy algorithms, healthcare digitalization, and healthcare policies.
- These factors form distinct clusters within the research landscape.
- Each identified direction significantly impacts patient adherence to injectable diabetes therapy.
Conclusions:
- Improving adherence to injectable diabetes treatment requires a multifaceted approach.
- Further in-depth research into each of the six identified factors is essential.
- Targeted interventions based on these factors can potentially enhance treatment adherence and patient outcomes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
226
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
226
01:15Diabetes: Management and Pharmacotherapy
327
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
327
01:27Insulin Formulations: Types and Delivery
248
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
248
01:22Diabetes Mellitus: Overview and Type I Subtype
2.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.9K
01:22Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
01:06Oral Hypoglycemic Agents: Glinides
211
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
211